Soliris eculizumab hematology data

Pooled data from 195 patients enrolled in a pilot trial, the Phase III TRIUMPH and SHEPHERD trials and their subsequent extension studies showed that Soliris reduced intravascular hemolysis in 100% of patients and significantly reduced lactate dehydrogenase (LDH) from a median of 2,133 U/L at baseline to 310 U/L at 1 month (p<0.0001). Furthermore, the reduction was sustained at 272 U/L at 36 months (p<0.0001). Soliris also significantly reduced the number of thromboembolism events by 81% from 52 pre-treatment events to 10 trial events using a matched-time analysis (p<0.0005). Soliris was well tolerated. Of the 4 patient deaths that occurred during treatment, 1 was considered possibly related to Soliris. Data will be presented at the American Society of Hematology meeting in Orlando in December. ...